Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oxford BioDynamics ( (GB:OBD) ) has provided an update.
Oxford BioDynamics, a UK-based precision clinical diagnostics company listed on AIM, specializes in blood-based tests built on its EpiSwitch 3D genomics platform to improve early disease detection and therapy selection. Its commercial portfolio currently includes high-accuracy tests for prostate cancer screening and predicting responses to checkpoint inhibitor treatments, and it is extending this technology across multiple therapeutic areas.
The company has appointed Singer Capital Markets Advisory as its new Nominated Adviser and Broker, a move that may strengthen its capital markets support and investor engagement on London’s AIM market. The change in adviser could enhance Oxford BioDynamics’ market positioning and access to funding as it advances development and commercialization of its expanding suite of EpiSwitch-based diagnostic tests.
The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.30 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Spark’s Take on GB:OBD Stock
According to Spark, TipRanks’ AI Analyst, GB:OBD is a Neutral.
The score is primarily constrained by weak financial performance—ongoing losses, high leverage, and worsening free cash flow trends. Technical indicators provide some near-term support (price above 20/50-DMAs and positive MACD), but longer-term moving averages remain overhead. Valuation is also pressured by negative earnings (negative P/E) and no stated dividend yield.
To see Spark’s full report on GB:OBD stock, click here.
More about Oxford BioDynamics
Oxford BioDynamics is an international biotechnology company focused on precision clinical diagnostics for life-changing diseases. It develops and commercializes blood-based tests leveraging its proprietary EpiSwitch 3D genomics platform to predict disease presence and treatment response.
The company’s key products include the EpiSwitch Prostate Screening test, which significantly enhances the accuracy of PSA-based prostate cancer detection, and the EpiSwitch Checkpoint Inhibitor Response Test, which predicts patient response to immuno-oncology therapies. It is expanding its test portfolio into oncology, neurology, inflammation, hepatology and animal health, with operations in the UK, US and Malaysia and a listing on London’s AIM market.
Average Trading Volume: 25,765,503
Technical Sentiment Signal: Sell
Current Market Cap: £12.87M
Learn more about OBD stock on TipRanks’ Stock Analysis page.